Skip to main content
main-content

01.12.2012 | Meeting report | Ausgabe 1/2012 Open Access

Malaria Journal 1/2012

Rationale for short course primaquine in Africa to interrupt malaria transmission

Zeitschrift:
Malaria Journal > Ausgabe 1/2012
Autoren:
Alice C Eziefula, Roly Gosling, Jimee Hwang, Michelle S Hsiang, Teun Bousema, Lorenz von Seidlein, Chris Drakeley
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1475-2875-11-360) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ACE, RG and CD wrote and edited the manuscript, ACE, MH and JH were meeting rapporteurs and together with TB and LvS, contributed to the manuscript. All authors read and approved the final manuscript.

Abstract

Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria. The drug has scarcely been used in Africa because of concerns about its safety in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The evidence base for the use of primaquine as a transmission blocker is limited by a lack of comparable clinical and parasitological endpoints between trials. In March 2012, a group of experts met in London to discuss the existing evidence on the ability of primaquine to block malaria transmission, to define the roadblocks to the use of primaquine in Africa and to develop a roadmap to enable its rapid, safe and effective deployment. The output of this meeting is a strategic plan to optimize trial design to reach desired goals efficiently. The roadmap includes suggestions for a series of phase 1, 2, 3 and 4 studies to address specific hurdles to primaquine’s deployment. These include ex-vivo studies on efficacy, primaquine pharmacokinetics and pharmacodynamics and dose escalation studies for safety in high-risk groups. Phase 3 community trials are proposed, along with Phase 4 studies to evaluate safety, particularly in pregnancy, through pharmacovigilance in areas where primaquine is already deployed. In parallel, efforts need to be made to address issues in drug supply and regulation, to map G6PD deficiency and to support the evaluation of alternative gametocytocidal compounds.
Zusatzmaterial
Authors’ original file for figure 1
12936_2012_2504_MOESM1_ESM.pdf
Authors’ original file for figure 2
12936_2012_2504_MOESM2_ESM.pdf
Authors’ original file for figure 3
12936_2012_2504_MOESM3_ESM.pdf
Authors’ original file for figure 4
12936_2012_2504_MOESM4_ESM.pdf
Authors’ original file for figure 5
12936_2012_2504_MOESM5_ESM.pdf
Authors’ original file for figure 6
12936_2012_2504_MOESM6_ESM.pdf
Authors’ original file for figure 7
12936_2012_2504_MOESM7_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Malaria Journal 1/2012 Zur Ausgabe

Neu im Fachgebiet Innere Medizin


 

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise